Interview with Roland Staack (Roche) on the nomenclature for large molecule assays recently developed at Roche

We sat down with Roland Staack (Roche) at the latest EBF 8th Open Meeting discussing the confusion caused by the current nomenclature for large-molecule drugs, and how this confusion may lead to misleading ‘active’ drug data. Roland also details the descriptive nomenclature, based on the therapeutics functionality, developed and implemented at Roche.